Received Jun 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
I developed a squamous cell in situ on my trunk or rib area; This serious case was reported by a consumer via interactive digital media and described the occurrence of squamous cell carcinoma in situ in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced squamous cell carcinoma in situ (Verbatim: I developed a squamous cell in situ on my trunk or rib area) (serious criteria GSK medically significant).The outcome of the squamous cell carcinoma in situ was not reported. It was unknown if the reporter considered the squamous cell carcinoma in situ to be related to Shingrix. The company considered the squamous cell carcinoma in situ to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 29-MAY-2026 This case was reported by a patient via interactive digital media. The patient got the Shingrix vaccine however, after the first shot, patient developed a squamous cell in situ on trunk or rib area. The patient said that's patient had never seen the sun and was coincidence maybe and patient still think the vaccine was worth it. The batch number was not provided and we and unable to contact the reporter.; Sender's Comments: A case of squamous cell carcinoma, unknown time after receiving Shingrix, in a patient. Based on the available information, a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.